Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Δ32 heterozygote

Virology

Volumn 362, Issue 1, 2007, Pages 163-178

  Gorry, Paul R ^a,b   Dunfee, Rebecca L ^a,b   Mefford, Megan E ^a,b   Kunstman, Kevin ^c   Morgan, Tom ^d   Moore, John P ^d   Mascola, John R ^e   Agopian, Kristin ^a,b   Holm, Geoffrey H ^a,b   Mehle, Andrew ^a,b   Taylor, Joann ^c   Farzan, Michael ^a,b   Wang, Hui ^a   Ellery, Philip ^f,g   Willey, Samantha J ^h   Clapham, Paul R ^h   Wolinsky, Steven M ^c   Crowe, Suzanne M ^f,g   Gabuzda, Dana ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

CCR5; CCR5 32; Env; HIV 1; V3

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 120;

AMINO TERMINAL SEQUENCE; ARTICLE; GENETIC TRANSFECTION; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MALE; MONOCYTE; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS ISOLATION;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CELL LINE; CELLS, CULTURED; HETEROZYGOTE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247262093     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.11.025     Document Type: Article

References (76)

1. Allaway G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., Hasel K.W., Gauduin M.C., Koup R.A., McDougal J.S., et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11 5 (1995) 533-539
2. Ancuta P., Bakri Y., Chomont N., Hocini H., Gabuzda D., and Haeffner-Cavaillon N. Opposite effects of IL-10 on the ability of dendritic cells and macrophages to replicate primary CXCR4-dependent HIV-1 strains. J. Immunol. 166 6 (2001) 4244-4253
3. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96 10 (1999) 5698-5703
4. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
5. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., and Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71 10 (1997) 7478-7487
6. Burton D.R., Barbas III C.F., Persson M.A., Koenig S., Chanock R.M., and Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U.S.A. 88 22 (1991) 10134-10137
7. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 5187 (1994) 1024-1027
8. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., and Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 7 (1996) 1135-1148
9. Choe H., Farzan M., Konkel M., Martin K., Sun Y., Marcon L., Cayabyab M., Berman M., Dorf M.E., Gerard N., Gerard C., and Sodroski J. The orphan seven-transmembrane receptor Apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J. Virol. 72 7 (1998) 6113-6118
10. Churchill M., Sterjovski J., Gray L., Cowley D., Chatfield C., Learmont J., Sullivan J.S., Crowe S.M., Mills J., Brew B.J., Wesselingh S.L., McPhee D.A., and Gorry P.R. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J. Infect. Dis. 190 12 (2004) 2181-2186
11. Churchill M.J., Rhodes D.I., Learmont J.C., Sullivan J.S., Wesselingh S.L., Cooke I.R., Deacon N.J., and Gorry P.R. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J. Virol. 80 2 (2006) 1047-1052
12. Cilliers T., Willey S., Sullivan W.M., Patience T., Pugach P., Coetzer M., Papathanasopoulos M., Moore J.P., Trkola A., Clapham P., and Morris L. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology 339 (2005) 136-144
13. Cohen O.J., Vaccarezza M., Lam G.K., Baird B.F., Wildt K., Murphy P.M., Zimmerman P.A., Nutman T.B., Fox C.H., Hoover S., Adelsberger J., Baseler M., Arthos J., Davey Jr. R.T., Dewar R.L., Metcalf J., Schwartzentruber D.J., Orenstein J.M., Buchbinder S., Saah A.J., Detels R., Phair J., Rinaldo C., Margolick J.B., Pantaleo G., and Fauci A.S. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J. Clin. Invest. 100 6 (1997) 1581-1589
14. Connor R.I., Sheridan K.E., Ceradini D., Choe S., and Landau N.R. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185 4 (1997) 621-628
15. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270 5238 (1995) 988-991
16. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., and O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 5283 (1996) 1856-1862
17. de Roda Husman A.M., van Rij R.P., Blaak H., Broersen S., and Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J. Infect. Dis. 180 4 (1999) 1106-1115
18. Doms R.W., and Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 14 21 (2000) 2677-2688
19. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., and Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4 1 (1998) 72-77
20. Dragic T., Trkola A., Lin S.W., Nagashima K.A., Kajumo F., Zhao L., Olson W.C., Wu L., Mackay C.R., Allaway G.P., Sakmar T.P., Moore J.P., and Maddon P.J. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72 1 (1998) 279-285
21. Edinger A.L., Hoffman T.L., Sharron M., Lee B., Yi Y., Choe W., Kolson D.L., Mitrovic B., Zhou Y., Faulds D., Collman R.G., Hesselgesser J., Horuk R., and Doms R.W. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 72 10 (1998) 7934-7940
22. Etemad-Moghadam B., Sun Y., Nicholson E.K., Fernandes M., Liou K., Gomila R., Lee J., and Sodroski J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 74 9 (2000) 4433-4440
23. Eugen-Olsen J., Iversen A.K., Garred P., Koppelhus U., Pedersen C., Benfield T.L., Sorensen A.M., Katzenstein T., Dickmeiss E., Gerstoft J., Skinhoj P., Svejgaard A., Nielsen J.O., and Hofmann B. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. Aids 11 3 (1997) 305-310
24. Farzan M., Choe H., Vaca L., Martin K., Sun Y., Desjardins E., Ruffing N., Wu L., Wyatt R., Gerard N., Gerard C., and Sodroski J. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72 2 (1998) 1160-1164
25. Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M., Gerard N.P., Gerard C., Sodroski J., and Choe H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96 5 (1999) 667-676
26. Gorry P.R., Bristol G., Zack J.A., Ritola K., Swanstrom R., Birch C.J., Bell J.E., Bannert N., Crawford K., Wang H., Schols D., De Clercq E., Kunstman K., Wolinsky S.M., and Gabuzda D. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 75 21 (2001) 10073-10089
27. Gorry P.R., Taylor J., Holm G.H., Mehle A., Morgan T., Cayabyab M., Farzan M., Wang H., Bell J.E., Kunstman K., Moore J.P., Wolinsky S.M., and Gabuzda D. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76 12 (2002) 6277-6292
28. Gorry P.R., Zhang C., Wu S., Kunstman K., Trachtenberg E., Phair J., Wolinsky S., and Gabuzda D. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 359 9320 (2002) 1832-1834
29. Gray L., Sterjovski J., Churchill M., Ellery P., Nasr N., Lewin S.R., Crowe S.M., Wesselingh S., Cunningham A.L., and Gorry P.R. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 337 (2005) 384-398
30. Hartley O., Klasse P.J., Sattentau Q.J., and Moore J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 21 2 (2005) 171-189
31. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., Kang S., Ceradini D., Jin Z., Yazdanbakhsh K., Kunstman K., Erickson D., Dragon E., Landau N.R., Phair J., Ho D.D., and Koup R.A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2 11 (1996) 1240-1243
32. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 5750 (2005) 1025-1028
33. Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., and Desrosiers R.C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332 4 (1995) 228-232
34. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., and Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75 7 (2001) 3435-3443
35. Kuhmann S.E., Platt E.J., Kozak S.L., and Kabat D. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J. Virol. 71 11 (1997) 8642-8656
36. Kuhmann S.E., Platt E.J., Kozak S.L., and Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74 15 (2000) 7005-7015
37. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., Strizki J.M., Riley J., Baroudy B.M., Wilson I.A., Korber B.T., Wolinsky S.M., and Moore J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78 6 (2004) 2790-27807
38. Lathey J.L., Tierney C., Chang S.Y., D'Aquila R.T., Bettendorf D.M., Alexander H.C., Santini C.D., Hughes A.M., Barroga C.F., Spector S.A., Landes J.E., Hammer S.M., and Katzenstein D.A. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J. Infect. Dis. 184 11 (2001) 1402-1411
39. Lawson V.A., Silburn K.A., Gorry P.R., Paukovic G., Purcell D.F., Greenway A.L., and McPhee D.A. Apoptosis induced in synchronized human immunodeficiency virus type 1-infected primary peripheral blood mononuclear cells is detected after the peak of CD4+ T-lymphocyte loss and is dependent on the tropism of the gp120 envelope glycoprotein. Virology 327 1 (2004) 70-82
40. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., Berg E., Liu G., Guy H.R., Durell S.R., Parmentier M., Chang C.N., Price K., Tsang M., and Doms R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274 14 (1999) 9617-9626
41. Mascola J.R., Louder M.K., Winter C., Prabhakara R., De Rosa S.C., Douek D.C., Hill B.J., Gabuzda D., and Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76 10 (2002) 4810-4821
42. Michael N.L., Chang G., Louie L.G., Mascola J.R., Dondero D., Birx D.L., and Sheppard H.W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3 3 (1997) 338-340
43. Morner A., Bjorndal A., Albert J., Kewalramani V.N., Littman D.R., Inoue R., Thorstensson R., Fenyo E.M., and Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73 3 (1999) 2343-2349
44. Moore J.P., Kitchen S.G., Pugach P., and Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20 1 (2004) 111-126
45. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., and Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68 6 (1994) 4031-4034
46. Nabatov A.A., Pollakis G., Linnemann T., Kliphius A., Chalaby M.I., and Paxton W.A. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J. Virol. 78 1 (2004) 524-530
47. Neil S.J., Aasa-Chapman M.M., Clapham P.R., Nibbs R.J., McKnight A., and Weiss R.A. The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J. Virol. 79 15 (2005) 9618-9624
48. Nibbs R.J., Wylie S.M., Yang J., Landau N.R., and Graham G.J. Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J. Biol. Chem. 272 51 (1997) 32078-32083
49. Nibbs R.J., Kriehuber E., Ponath P.D., Parent D., Qin S., Campbell J.D., Henderson A., Kerjaschki D., Maurer D., Graham G.J., and Rot A. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am. J. Pathol. 158 3 (2001) 867-877
50. O'Brien S.J., and Moore J.P. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177 (2000) 99-111
51. Olson W.C., Rabut G.E., Nagashima K.A., Tran D.N., Anselma D.J., Monard S.P., Segal J.P., Thompson D.A., Kajumo F., Guo Y., Moore J.P., Maddon P.J., and Dragic T. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73 5 (1999) 4145-4155
52. Pastore C., Nedellec R., Ramos A., Pontow S., Ratner L., and Mosier D.E. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J. Virol. 80 2 (2006) 750-758
53. Platt E.J., Kuhmann S.E., Rose P.P., and Kabat D. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. J. Virol. 75 24 (2001) 12266-12278
54. Platt E.J., Shea D.M., Rose P.P., and Kabat D. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J. Virol. 79 7 (2005) 4357-4368
55. Rabut G.E., Konner J.A., Kajumo F., Moore J.P., and Dragic T. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dual tropic isolates of human immunodeficiency virus type 1. J. Virol. 72 4 (1998) 3464-3468
56. Reeves J.D., McKnight A., Potempa S., Simmons G., Gray P.W., Power C.A., Wells T., Weiss R.A., and Talbot S.J. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 231 1 (1997) 130-134
57. Reeves J.D., Hibbitts S., Simmons G., McKnight A., Azevedo-Pereira J.M., Moniz-Pereira J., and Clapham P.R. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J. Virol. 73 9 (1999) 7795-7804
58. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., and Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280 5371 (1998) 1949-1953
59. Roger M. Influence of host genes on HIV-1 disease progression. FASEB J. 12 9 (1998) 625-632
60. Rucker J., Samson M., Doranz B.J., Libert F., Berson J.F., Yi Y., Smyth R.J., Collman R.G., Broder C.C., Vassart G., Doms R.W., and Parmentier M. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87 3 (1996) 437-446
61. Rucker J., Edinger A.L., Sharron M., Samson M., Lee B., Berson J.F., Yi Y., Margulies B., Collman R.G., Doranz B.J., Parmentier M., and Doms R.W. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71 12 (1997) 8999-9007
62. Schols D., Struyf S., Van Damme J., Este J.A., Henson G., and De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186 8 (1997) 1383-1388
63. Shioda T., Oka S., Xin X., Liu H., Harukuni R., Kurotani A., Fukushima M., Hasan M.K., Shiino T., Takebe Y., Iwamoto A., and Nagai Y. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J. Virol. 71 7 (1997) 4871-4881
64. Siciliano S.J., Kuhmann S.E., Weng Y., Madani N., Springer M.S., Lineberger J.E., Danzeisen R., Miller M.D., Kavanaugh M.P., DeMartino J.A., and Kabat D. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J. Biol. Chem. 274 4 (1999) 1905-1913
65. Simmons G., Reeves J.D., McKnight A., Dejucq N., Hibbitts S., Power C.A., Aarons E., Schols D., De Clercq E., Proudfoot A.E., and Clapham P.R. CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J. Virol. 72 10 (1998) 8453-8457
66. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., Goedert J.J., O'Brien T.R., Jacobson L.P., Kaslow R., Buchbinder S., Vittinghoff E., Vlahov D., Hoots K., Hilgartner M.W., and O'Brien S.J. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277 5328 (1997) 959-965
67. Solomon A., Lane N., Wightman F., Gorry P.R., and Lewin S.R. Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts. J. Acquired Immune Defic. Syndr. 40 2 (2005) 140-148
68. Sullivan N., Thali M., Furman C., Ho D.D., and Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67 6 (1993) 3674-3679
69. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 11 (1995) 6609-6617
70. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
71. Trkola A., Paxton W.A., Monard S.P., Hoxie J.A., Siani M.A., Thompson D.A., Wu L., Mackay C.R., Horuk R., and Moore J.P. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 72 1 (1998) 396-404
72. Wang B., Spira T.J., Owen S., Lal R.B., and Saksena N.K. HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. Aids 14 3 (2000) 213-223
73. Willey S.J., Reeves J.D., Hudson R., Miyake K., Dejucq N., Schols D., De Clercq E., Bell J., McKnight A., and Clapham P.R. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. J. Virol. 77 11 (2003) 6138-6152
74. Xiang S.H., Farzan M., Si Z., Madani N., Wang L., Rosenberg E., Robinson J., and Sodroski J. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J. Virol. 79 10 (2005) 6068-6077
75. Zhang L., He T., Huang Y., Chen Z., Guo Y., Wu S., Kunstman K.J., Brown R.C., Phair J.P., Neumann A.U., Ho D.D., and Wolinsky S.M. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 72 11 (1998) 9307-9312
76. Zhang P.F., Bouma P., Park E.J., Margolick J.B., Robinson J.E., Zolla-Pazner S., Flora M.N., and Quinnan Jr. G.V. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76 2 (2002) 644-655